Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Joly

Showing results (21-30 of 226) with videos related to

Pageof 23
Sort By:
Journal of Oleo Science|January 28, 2010
Preparation of highly water-repellent surface by spontaneous formation of double scale roughness patternPascal Joly, Akihiro Kuroda, Kouichi Asakura
The New England Journal of Medicine|February 3, 2007
Rituximab for pemphigus vulgarisPascal Joly, Michel D'Incan, Philippe Musette
Frontiers in Immunology|August 15, 2020
Editorial: Autoimmune Blistering DiseasesCezary Kowalewski, Takashi Hashimoto, Pascal Joly
Dermatologic Clinics|September 20, 2011
Management of autoimmune bullous diseases in France: a nationwide network of 30 centersNicolas Meyer, Carle Paul, Pascal Joly
Italian Journal of Dermatology and Venereology|October 19, 2020
Paraneoplastic autoimmune multiorgan syndromeDario Didona, Giovanni DI Zenzo, Pascal Joly
The Journal of Dermatology|April 15, 2003
Treatment of bullous pemphigoidJuliette Fontaine, Pascal Joly, Jean-Claude Roujeau
Health (London, England : 1997)|January 7, 2022
Taking care of oneself and others: The emotion work of women suffering from a rare skin diseaseYannick Le Henaff, Stéphane Héas, Pascal Joly
Drugs & Aging|July 26, 2005
The role of topical corticosteroids in bullous pemphigoid in the elderlyPascal Joly, Juliette Fontaine, Jean-Claude Roujeau
Journal of the American Academy of Dermatology|March 13, 2021
Individual patients' risk factors impact guidelines for prophylactic agents used in pemphigus patients treated with rituximabDedee F Murrell, Pascal Joly, Victoria P Werth
Clinics in Dermatology|September 14, 2021
Impact of COVID-19 on autoimmune blistering diseasesKossara Drenovska, Snejina Vassileva, Ivan Tanev, et al.
Pageof 23

Showing results (21-30 of 226) with videos related to

Sort By:
Pageof 23
Journal of Oleo Science|January 28, 2010
Preparation of highly water-repellent surface by spontaneous formation of double scale roughness patternPascal Joly, Akihiro Kuroda, Kouichi Asakura
The New England Journal of Medicine|February 3, 2007
Rituximab for pemphigus vulgarisPascal Joly, Michel D'Incan, Philippe Musette
Frontiers in Immunology|August 15, 2020
Editorial: Autoimmune Blistering DiseasesCezary Kowalewski, Takashi Hashimoto, Pascal Joly
Dermatologic Clinics|September 20, 2011
Management of autoimmune bullous diseases in France: a nationwide network of 30 centersNicolas Meyer, Carle Paul, Pascal Joly
Italian Journal of Dermatology and Venereology|October 19, 2020
Paraneoplastic autoimmune multiorgan syndromeDario Didona, Giovanni DI Zenzo, Pascal Joly
The Journal of Dermatology|April 15, 2003
Treatment of bullous pemphigoidJuliette Fontaine, Pascal Joly, Jean-Claude Roujeau
Health (London, England : 1997)|January 7, 2022
Taking care of oneself and others: The emotion work of women suffering from a rare skin diseaseYannick Le Henaff, Stéphane Héas, Pascal Joly
Drugs & Aging|July 26, 2005
The role of topical corticosteroids in bullous pemphigoid in the elderlyPascal Joly, Juliette Fontaine, Jean-Claude Roujeau
Journal of the American Academy of Dermatology|March 13, 2021
Individual patients' risk factors impact guidelines for prophylactic agents used in pemphigus patients treated with rituximabDedee F Murrell, Pascal Joly, Victoria P Werth
Clinics in Dermatology|September 14, 2021
Impact of COVID-19 on autoimmune blistering diseasesKossara Drenovska, Snejina Vassileva, Ivan Tanev, et al.
Pageof 23